Remission and regression of diabetic nephropathy

被引:23
作者
Hovind, P [1 ]
Tarnow, L [1 ]
Parving, HH [1 ]
机构
[1] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
关键词
D O I
10.1007/s11906-004-0057-x
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Diabetic kidney disease is considered to be an irreversible and inexorable progressive disease. Therefore, prevention of development of ESRD is extremely important. Animal studies have demonstrated that regression of existing renal morphologic lesions is feasible. In a sizable fraction of type I diabetic patients with overt nephropathy, remission (decrease in albuminuria to <300 mg/24h) was obtained (31%), and regression of diabetic nephropathy (rate of decline in GFR <= 1 ml/min/y), achieved (22%) by aggressive antihypertensive treatment. Furthermore, remission of nephrotic-range albuminuria (from > 2500 mg/24 h to < 600 mg/24h) have been demonstrated to be achievable in one fifth of patients with nephrotic-range albuminuria was associated with reduction in decline in GFR and improved survival free of ESRD. However, to prevent development of ESRD in diabetic patients, an aggressive multifactorial approach aiming at lowering blood pressure and albuminuria and improving glycemic control must be applied.
引用
收藏
页码:377 / 382
页数:6
相关论文
共 46 条
[1]  
ABOUNA GM, 1983, LANCET, V2, P1274
[2]   Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats [J].
Adamczak, M ;
Gross, ML ;
Krtil, J ;
Koch, A ;
Tyralla, K ;
Amann, K ;
Ritz, E .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (11) :2833-2842
[3]  
ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496
[4]   Long-term renoprotective effects of losartan in diabetic nephropathy [J].
Andersen, S ;
Tarnow, L ;
Cambien, F ;
Rossing, P ;
Juhl, TR ;
Deinum, J ;
Parving, HH .
DIABETES CARE, 2003, 26 (05) :1501-1506
[5]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]
[6]  
AUSTIN SM, 1993, J AM SOC NEPHROL, V3, P1358
[7]   RENAL PROTECTIVE EFFECT OF ENALAPRIL IN DIABETIC NEPHROPATHY [J].
BJORCK, S ;
MULEC, H ;
JOHNSEN, SA ;
NORDEN, G ;
AURELL, M .
BMJ-BRITISH MEDICAL JOURNAL, 1992, 304 (6823) :339-343
[8]   THE EFFECT OF PROTEINURIA ON RELATIVE MORTALITY IN TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS [J].
BORCHJOHNSEN, K ;
ANDERSEN, PK ;
DECKERT, T .
DIABETOLOGIA, 1985, 28 (08) :590-596
[9]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[10]  
DEZEEUW D, 2004, IN PRESS CIRCULATION